OTCMKTS:UCBJF - UCB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $116.77
  • Forecasted Upside: 0.88 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$115.75
+0.30 (1.20%)

This chart shows the closing price for UCBJF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New UCB Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UCBJF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UCBJF

Analyst Price Target is $116.77
▲ +0.88% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for UCB in the last 3 months. The average price target is $116.77, with a high forecast of $150.00 and a low forecast of $91.00. The average price target represents a 0.88% upside from the last price of $115.75.

This chart shows the closing price for UCBJF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in UCB. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/3/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/1/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/29/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/24/2021Berenberg BankInitiated CoverageBuy
10/19/2021BarclaysDowngradeHold$91.00
9/16/2021Jefferies Financial GroupUpgradeBuy$130.00
9/2/2021JPMorgan Chase & Co.UpgradeBuy$150.00
8/23/2021UBS GroupUpgradeBuy$116.00
7/23/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuy$105.39
7/12/2021BNP ParibasUpgradeBuy$110.00
7/9/2021Societe GeneraleInitiated CoverageBuy$115.00
7/31/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
6/16/2020JPMorgan Chase & Co.Reiterated RatingOverweight
6/15/2020BarclaysReiterated RatingOverweight
3/5/2020BarclaysReiterated RatingOverweight
10/16/2019CitigroupUpgradeNeutral ➝ Buy
9/11/2018Jefferies Financial GroupUpgradeUnderperform ➝ Hold
(Data available from 11/28/2016 forward)

News Sentiment Rating

0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/31/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2021

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
UCB logo
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
Read More

Today's Range

Now: $115.75
Low: $115.75
High: $115.75

50 Day Range

MA: $114.29
Low: $106.00
High: $120.25

52 Week Range

Now: $115.75
Low: $93.00
High: $120.25

Volume

N/A

Average Volume

419 shs

Market Capitalization

$21.88 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of UCB?

The following sell-side analysts have issued reports on UCB in the last twelve months: Barclays PLC, Berenberg Bank, BNP Paribas, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., JPMorgan Chase & Co., Societe Generale, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for UCBJF.

What is the current price target for UCB?

7 Wall Street analysts have set twelve-month price targets for UCB in the last year. Their average twelve-month price target is $116.77, suggesting a possible upside of 0.9%. JPMorgan Chase & Co. has the highest price target set, predicting UCBJF will reach $150.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $91.00 for UCB in the next year.
View the latest price targets for UCBJF.

What is the current consensus analyst rating for UCB?

UCB currently has 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe UCBJF will outperform the market and that investors should add to their positions of UCB.
View the latest ratings for UCBJF.

How do I contact UCB's investor relations team?

UCB's physical mailing address is Allee de la Recherche 60, Brussels C9, 1070. The company's listed phone number is (322) 559-9999 and its investor relations email address is [email protected] The official website for UCB is www.ucb.com.